Ascendis Pharma (ASND) Q4 2025 earnings review
YORVIPATH Hypergrowth Eclipses Everything Else
Ascendis delivered a transformative quarter driven by the explosive adoption of YORVIPATH, which generated €187M in Q4 (up ~30% QoQ). The company has successfully pivoted from cash-burn to operating profitability (€10M in Q4), validating the commercial platform. While SKYTROFA is stagnating (down 9% YoY), the sheer velocity of YORVIPATH allowed management to guide for a massive inflection in 2026: €500M in Operating Cash Flow. The thesis has shifted from clinical risk to commercial execution, and Ascendis is executing flawlessly on its lead asset.
🐂 Bull Case
Revenue accelerated to €186.7M in Q4, implying a nearly €750M annual run rate just one year after launch. With full commercial launches in 10 additional countries planned for 2026, the runway is clear.
Management guided for €500M in Operating Cash Flow for 2026. This transforms the balance sheet risk profile, enabling a new $120M share repurchase program.
🐻 Bear Case
While YORVIPATH soars, SKYTROFA revenue fell 9% YoY to €53.4M. It has effectively plateaued around €50M/quarter for the last year, raising concerns about its long-term growth ceiling.
Despite €9.9M in operating profit, the company posted a €34M Net Loss due to €62M in finance expenses. The capital structure remains expensive relative to current earnings power.
⚖️ Verdict: 🟢🟢
Strong Buy. YORVIPATH's trajectory is undeniable, and the guidance for €500M operating cash flow in 2026 confirms the company has crossed the chasm from R&D burn to commercial cash machine.
Key Themes
YORVIPATH Velocity
The launch curve is exponential. Revenue jumped from €13.6M (24Q4) to €186.7M (25Q4). This single asset is driving the entire company's P&L improvement. The drug is now available in >30 countries, with patient enrollment continuing to scale.
SKYTROFA Growth Wall
SKYTROFA is underperforming. Revenue came in at €53.4M vs €58.5M a year ago. While 24Q4 had a one-time adjustment, the sequential trend is flat (€50-53M range for 4 quarters). Dependence on label expansions (Adult GHD approved July 2025) has not yet yielded a visible revenue inflection.
TransCon CNP Catalyst
The next leg of growth is imminent. PDUFA date for TransCon CNP (pediatric achondroplasia) is February 28, 2026. Given the success of YORVIPATH, the market will likely assign high probability to a successful commercial execution here.
Expense Discipline
Ascendis is demonstrating operating leverage. R&D expenses were effectively flat YoY (€78M vs €79M) despite pipeline progress. While SG&A rose to support the launch (€136M vs €80M), it was outpaced by the massive revenue growth (€248M vs €174M).
Bottom Line Disconnect
Operating profit is positive (€10M), but Net Loss persists (€34M). The culprit is €62M in finance expenses (up from €59M YoY). Until the company refinances or pays down debt with its incoming cash flow, EPS will lag operating performance.
Other KPIs
Accelerating. Up 42% YoY and up ~16% sequentially vs implied Q3 (~€214M). Growth is entirely driven by commercial product uptake.
Stable/High. Gross profit of €224M on €248M revenue. This high margin profile ensures that incremental YORVIPATH revenue drops almost directly to the operating line.
Strong. Cash increased by €77M vs Q3 (€539M), driven by positive operating cash flow (€73M in Q4). The company is now self-funding.
Guidance
Accelerating significantly. This is a massive jump from FY25 operating cash flow (which was negative for the full year despite a strong Q4). It implies huge profitability in 2026.
Stable. Management reiterated this long-term target, which implies a >30% CAGR from current run-rates.
New. Management is confident enough in the cash generation to return capital to shareholders immediately, a rarity for a biotech just turning the corner to profitability.
Key Questions
SKYTROFA's Future
SKYTROFA revenue declined YoY. Is this simply base effects/pricing, or has the product reached saturation in the pediatric market before the adult launch gains traction?
Finance Expense Burden
With €62M in quarterly finance expenses wiping out operating profit, what is the plan to deleverage or refinance now that cash flow is positive?
YORVIPATH Retention
With such rapid enrollment, what are the discontinuation rates and compliance metrics looking like after 12 months on therapy?